Literature DB >> 27118934

When Should Therapy for Inflammatory Bowel Disease Be Stopped?

David T Rubin1.   

Abstract

Year:  2015        PMID： 27118934      PMCID： PMC4843034     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  18 in total

1.  Exposure to immunization media messages among African American parents.

Authors:  N Lashuay; T Tjoa; M L Zuniga de Nuncio; M Franklin; J Elder; M Jones
Journal:  Prev Med       Date:  2000-11       Impact factor: 4.018

2.  Long-term success with the national health objective for influenza vaccination: an institution-wide model.

Authors:  K L Nichol
Journal:  J Gen Intern Med       Date:  1992 Nov-Dec       Impact factor: 5.128

3.  Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Scott A Harper; Keiji Fukuda; Timothy M Uyeki; Nancy J Cox; Carolyn B Bridges
Journal:  MMWR Recomm Rep       Date:  2004-05-28

4.  A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD.

Authors:  Siddhartha Parker; Laura Chambers White; Chad Spangler; Jessica Rosenblum; Shannon Sweeney; Emily Homan; Steven P Bensen; L Campbell Levy; Maria Conception C Dragnev; Kristen Moskalenko-Locke; Pamela Rich; Corey A Siegel
Journal:  Inflamm Bowel Dis       Date:  2013-08       Impact factor: 5.325

5.  Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses.

Authors:  Gil Y Melmed; Andrew F Ippoliti; Konstantinos A Papadakis; Tram T Tran; Jaime L Birt; Susie K Lee; Robert W Frenck; Stephan R Targan; Eric A Vasiliauskas
Journal:  Am J Gastroenterol       Date:  2006-06-30       Impact factor: 10.864

6.  Vaccinations and the Utilization of Immunosuppressive IBD Therapy.

Authors:  Gil Y Melmed
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-12

Review 7.  Using a Treat-to-Target Management Strategy to Improve the Doctor-Patient Relationship in Inflammatory Bowel Disease.

Authors:  David T Rubin; Noa Krugliak Cleveland
Journal:  Am J Gastroenterol       Date:  2015-04-07       Impact factor: 10.864

8.  Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.

Authors:  Pauliina Molander; Martti Färkkilä; Kimmo Salminen; Helena Kemppainen; Timo Blomster; Ritva Koskela; Airi Jussila; Henna Rautiainen; Markku Nissinen; Johanna Haapamäki; Perttu Arkkila; Urpo Nieminen; Juha Kuisma; Jari Punkkinen; Kaija-Leena Kolho; Harri Mustonen; Taina Sipponen
Journal:  Inflamm Bowel Dis       Date:  2014-06       Impact factor: 5.325

Review 9.  Improving quality of care in inflammatory bowel disease: what changes can be made today?

Authors:  Julián Panés; Marian O'Connor; Laurent Peyrin-Biroulet; Peter Irving; Joel Petersson; Jean-Frédéric Colombel
Journal:  J Crohns Colitis       Date:  2014-04-06       Impact factor: 9.071

10.  An effective hospital-based pneumococcal immunization program.

Authors:  R S Klein; N Adachi
Journal:  Arch Intern Med       Date:  1986-02
View more
  2 in total

1.  Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.

Authors:  Anthony Buisson; Wing Yan Mak; Michael J Andersen; Donald Lei; Stacy A Kahn; Joel Pekow; Russel D Cohen; Nada Zmeter; Bruno Pereira; David T Rubin
Journal:  J Crohns Colitis       Date:  2019-08-14       Impact factor: 9.071

2.  A Machine Learning Model Accurately Predicts Ulcerative Colitis Activity at One Year in Patients Treated with Anti-Tumour Necrosis Factor α Agents.

Authors:  Iolanda Valentina Popa; Alexandru Burlacu; Catalina Mihai; Cristina Cijevschi Prelipcean
Journal:  Medicina (Kaunas)       Date:  2020-11-20       Impact factor: 2.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.